print version 

Find company
Home About the ProjectContact usFor the Clients
Enter code or ISIN
 
alpha / industry search

Issuers' Corner
Press Releases
Annual Reports Library

Financial Statements
SEC & FFMS Filings
Corporate Presentations
GM Materials
Issues Documents
Corporate Governance Materials
Russian Company Guide
Company Profiles
Corporate Calendar
Markets Corner
Consensus Estimates
Media Corner
News Line


Get updates



Home  Issuers' Corner  Press Releases REGISTER LOG IN

Press Releases

company search
all press releases
all Pharmstandard press releases

Pharmstandard

February 17, 2009

JSC Pharmstandard reports 2008 sales results

Moscow, 17 February, 2009 – JSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) announces its unaudited 2008 sales results. The total revenue of the Company for the year increased by 28% and achieved RUR14,565 million (or US$586[1] million).

Other highlights:

· Pharmstandard has been included into the list of strategic companies by the Government of the Russian Federation;

· Pharmstandard obtained European Union Good Manufacturing Practice (EU GMP) certifications for 6 production lines of JSC «Pharmstandard-Leksredstva»;

· International group of well-known scientists published the results of study of the mode of action of antiviral drug Arbidol® in the leading international virology journal - Antiviral Research (2009 Feb;81(2):132 -40). The study and the fact of publication of its results in major scientific peer-review journal confirm direct antiviral effect of Arbidol® bringing it into the line with worldwide-known anti-influenza medicines such as ozeltamivir. The sales of Arbidol® grew by 18% in 2008 and achieved RUR2,731 million.

· Pharmstandard acquired the Afobazol® trade mark from Donelle Company Limited entirely financed from the own funds. Afobazol® is the new original selective anxiolytic for anxiety disorders treatment and is patent protected until 2019. Pharmstandard’s sales of Afobazol® started in August 2008 and reached RUR218 million;

· Mildronate® project with Grindex developed well. Mildronate® sales achieved RUR1,368 million in 2008 and grew by 41%[2];

· Pharmstandard announces successful development of SOLMIR project. According to the agreement with Solvay Pharmaceuticals (France), Pharmstandard will produce 2 immunomodulating products - IRS19® and Imudon®.  The sales of IRS19® has been recently started and achieved RUR31 million in December 2008;

· Pharmstandard’s gene-engineering products showed noticeable dynamic. The sales of Biosulin® grew by 36% to RUR164 million; 

· From the beginning of the year, the Company launched 14 new products: Bloctran®, Influnorm®, Combilipen®, Complivit® ophtalmo, Complivit® Se, Complivit® Fe, Complivit® Mg,  Neipomax®, Neirocomplit®, Octolipen®, Neosmectin®, Lactazar®, Formetin® and Pentalgin® Plus. New products contribution was RUR 212 million in 2008.

Sales

In 2008 Pharmstandard’s sales increased by 28% to RUR14,565 million (US$586 million), which represents the increase of RUR3,193 million in comparison with RUR11,371 million in 2007. Pharmaceutical products and medical equipment sales contributed 93% and 7% of total sales respectively. Sales growth for 9 months of 2008 was 34% and 26% in 4th quarter of 2008.

In 2008 the Company’s sales of pharmaceutical products achieved RUR13,488 million (US$542 million) and increased by 38% compared to 2007.

The sales of OTC products were RUR10,567 million (US$425 million) in 2008 and grew by 24% in comparison with prior-year period. Arbidol®, Terpincod®, Pentalgin®, Complivit®, Codelac®, Flukostat® (tablets), Amixin® and Afobazol® generated key sales growth in OTC segment.  OTC segment sales growth excluding Afobazol® and IRS 19® sales were 23% in 2008.

The Company’s revenue from prescription (Rx) products amounted to RUR2,856 million (US$115 million) and increased by 140% compared with 2007. This increase in prescription sales was attributed to successful development of Mildronate® project as well as an increase in leading brands sales, such as Phosphogliv®, Biosulin®, Cyclodol®, Pikamilon® and Renipril®. Rx segment sales growth excluding Mildronate® sales was 25%.

In 2008 the Company reported revenues of RUR1,077 million (US$43 million) from its medical equipment business, which represents a 33% decline in comparison with 2007 and generally attributable to the government tender sales in 2007.

Sales structure – FY 2008, RUR mln.

 

2008 (mln RUR)

2007 (mln RUR)*

Change (mln RUR)

Change, %

Pharmaceutical products

13 488

9 763

3 725

38%

OTC products

10 567

8 520

2 047

24%

Prescription products

2 856

1 188

1 668

140%

including

 

 

 

 

     Mildronate

1 368

0

1 368

-

Other sales

65

55

10

19%

Medical equipment and disposables

1 077

1 609

-532

-33%

Total sales

14 565

11 371

3 193

28%

* - restated numbers, according to 2008 OTC/Rx reclassification


Sales structure – 4Q 2008, RUR mln.

 

4Q 2008 (mln RUR)

4Q 2007 (mln RUR) *

Change (mln RUR)

Change, %

Pharmaceutical products

3 925

3 109

816

26%

OTC products

3 020

2 797

223

8%

Prescription products

865

296

569

193%

including

 

 

 

 

     Mildronate

478

0

478

-

Other sales

40

17

23

136%

Medical equipment and disposables

280

507

-227

-45%

Total sales

4 205

3 616

589

16%

* - restated numbers, according to 2008 OTC/Rx reclassification

Market

According to Pharmexpert data, Pharmstandard is one of largest pharmaceutical companies operating in Russia[3]. Pharmstandard is a leader of the biggest commercial segment of the Russian pharmaceutical segment[4]. Pharmstandard is the only one among domestic pharmaceutical companies which ranked in TOP10 market leaders.

Pharmstandard is the only pharmaceutical company at the Russian market which has 6 brands  among top-10 (in comparison with 6 brands in top-20 in 2008) best selling domestic brands in Russia such as Arbidol®, Pentalgin®, Terpincod®, Complivit®, Codelac®, Flucostat® and Amixin®.

Conference Call

Pharmstandard is pleased to invite the investment community to a sales results conference call with the management of the company followed by a Q&A session.

Tuesday, February 17, 2009

09:00 New York

14:00 London

17:00 Moscow

International Call-in Number:  +44 (0)20 7162 0025
Free Phone (US Only): +1 877 491 0064

Conference call presentation will be available on Tuesday, 17 February 2009 on Company’s web-site:

https://www.pharmstd.ru/investors_en/investor/p2/

We recommend that participants start dialling in 5-10 minutes prior to ensure a timely start to the conference call.
Conference call participants can register in advance using the link below:

https://eventreg1.conferencing.com/webportal3/reg.html?Acc=387058&Conf=164364

Pharmstandard will be represented by:

Igor Krylov, CEO
Elena Arkhangelskaya, CFO
Olga Mednikova, Sales & Marketing

The conference call replay will be available through February 20, 2009.

International Replay Number: +44 (0) 20 7031 4064
Toll Free Replay Number (US only): +1 888 365 0240
Replay Access Code: 826064

 

 

 

Search by industry

Agriculture, Foresty and Fishing | Chemicals | Engineering | Ferrous Metals | Financial, Insurance & Real Estate | Food & Kindred Products | General Construction | Information Technology | Media & Publishing | Non-Ferrous Metals | Oil & Gas | Pharmaceuticals | Power Industry | Precious Metals and Diamonds | Telecommunications | Transportation | Wholesale & Retail Trade

Search by alpha index

A B C D F G H I K L M N O P R S T U V W X Z


Site Map
© RUSTOCKS.com
Privacy Statement | Disclaimer